导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.24% | 2768/4773 |
| 近一周 | -1.92% | 3119/5465 |
| 近一月 | -3.62% | 2692/5421 |
| 近一季 | -6.84% | 2575/5231 |
| 近半年 | -2.25% | 2071/4920 |
| 近一年 | 1.55% | 2463/4394 |
| 近两年 | 48.54% | 1550/2954 |
| 近三年 | 29.62% | 1101/2253 |
| 成立以来 | 35.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.76% 3399/4961 |
12.53% 2163/5312 |
- - |
- - |
| 2025 | 20.55% 2111/4813 |
-1.06% 2563/3635 |
2.31% 1659/4076 |
18.87% 2235/4524 |
0.19% 2144/4813 |
| 2024 | 17.51% 682/3463 |
2.97% 647/2808 |
-1.19% 970/3014 |
17.81% 1115/3129 |
-1.97% 1908/3463 |
| 2023 | -9.52% 1182/2656 |
4.53% 929/2280 |
-4.08% 1038/2385 |
-3.08% 847/2515 |
-6.89% 1963/2655 |
| 2022 | -19.84% 907/2207 |
-14.50% 956/1919 |
7.15% 520/2016 |
-14.14% 1030/2113 |
1.91% 1092/2208 |
| 2021 | 0.99% 697/1822 |
-2.23% 603/1255 |
6.48% 745/1330 |
-4.53% 716/1466 |
1.62% 859/1822 |
| 2020 | 28.61% 558/1250 |
-10.86% 807/1028 |
13.81% 591/1067 |
10.84% 506/1164 |
14.38% 280/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安沪深300ETF VS. 长安沪深300非周期A(740101) |